Innovative Targeting Solutions Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Innovative Targeting Solutions Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/Canada/life-sciences/report/05IC-GDPH510049D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Innovative Targeting Solutions Inc – Pharmaceuticals & Healthcare…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Innovative Targeting Solutions Inc (ITS) focuses on the development of novel human antibody technologies. The company developed a next generation protein engineering platform which helps for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG technology. ITS’s utilizes its technology to develop its pipeline programs such as agonists, rare epitopes, complex membrane proteins for various therapeutic areas. HuTARG technology, is a fully mammalian technology which generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. The company conducts research collaborations with other organizations such as Merck; Amgen and Novartis, among others to identify and develop novel biologic therapeutic candidates. ITS is headquartered in Burnaby, British Columbia, Canada.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287378[/fusion_builder_row][/fusion_builder_container]

Kadimastem Ltd (KDST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Kadimastem Ltd (KDST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/Israel/life-sciences/report/05IC-GDPH408689D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Kadimastem Ltd (KDST) – Pharmaceuticals & Healthcare – Deals and…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Kadimastem Ltd (Kadimastem) is a biotechnology company that develops and commercializes stem cell-based therapeutics for diabetes and neurodegenerative disorders. The company offers human pluripotent stem cell technology, based on differentiation of human embryonic stem cells towards insulin producing beta cells, and glucagon producing alpha cells arranged in islet-like clusters. Its technology is a combination of purification capabilities with a specific differentiation process of the islet-like clusters. The company’s technology differentiates human pluripotent cells into mature oligodendrocytes, astrocytes, motoneurons, pancreatic beta cells and other cell types. Kadimastem is headquartered in Nes-Ziona, Israel.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287377[/fusion_builder_row][/fusion_builder_container]

Jitsubo Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Jitsubo Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/Japan/life-sciences/report/05IC-GDPH363757D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Jitsubo Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Jitsubo Co Ltd (Jitsubo), a subsidiary of Sosei Group Corp is a biotechnology company that develops, manufactures and commercializes peptide therapeutics. The company’s molecular hiving technology modifies the polysaccharide and sugar chain peptide sequence. Its Molecular Hiving technology has two part technologies such as thermomorphic system and hydrophobic tag. Jitsubo offer peptide synthesis to modify amino acid sequence for the creation of physical, chemical and pharmacological properties. The company also provides technology for collaborative research. It partners with other biotechnology companies for product optimization and process optimization. Jitsubo is headquartered in Koganei, Japan.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287376[/fusion_builder_row][/fusion_builder_container]

Janus Biotherapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Janus Biotherapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/United States/life-sciences/report/05IC-GDPH322110D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Janus Biotherapeutics Inc – Pharmaceuticals & Healthcare – Deals…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Janus Biotherapeutics Inc (Janus Biotherapeutics) develops therapies for the treatment of autoimmune diseases. The company develops oral compounds that aim to stop the abnormal toll-like receptor (TLR) 7, 8 and 9’s activation, which result in causing autoimmune diseases. Janus Biotherapeutics pipeline portfolio discovers and develops oral anti-TLR drug candidates for the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome, scleroderma, multiple sclerosis (MS), psoriasis and other autoimmune diseases.The company develops therapeutics in partnership with Roche Pharmaceuticals. Janus Biotherapeutics is headquartered in Wellesley, Massachusetts, the US.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287375[/fusion_builder_row][/fusion_builder_container]

InnaVirVax SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile

InnaVirVax SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/France/life-sciences/report/05IC-GDPH263946D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’InnaVirVax SA – Pharmaceuticals & Healthcare – Deals and Alliances…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

InnaVirVax SA (InnaVirVax) is a biopharmaceutical company which discovers and develops products for the treatment of HIV/AIDS infection pathologically and novel cancer therapies. The company’s pipeline product portfolio comprise DIAG-3S, an AIDS prognostic test; VAC-3S, an HIV AIDs therapeutic vaccine protecting the cd4+ t lymphocytes from depletion; VAC02, a vaccine project for the prophylactic vaccination against HIV injection, and others. InnaVirVax works in collaboration with pharmaceutical companies, biotechnology companies and research institutes for the further development and commercialization of its vaccine candidates. The company develops a potent vaccine technology platform which can generate high levels of antibodies targeted against the used peptide antigens. InnaVirVax is headquartered in Evry, France.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287374[/fusion_builder_row][/fusion_builder_container]

Klaria Pharma Holding AB (KLAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Klaria Pharma Holding AB (KLAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/Sweden/life-sciences/report/05IC-GDPH2517514D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Klaria Pharma Holding AB (KLAR) – Pharmaceuticals & Healthcare -…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Klaria Pharma Holding AB (Klaria Pharma) is a pharmaceutical company that discovers, develops and commercializes products for migraine and cancer related pain. The company’s patented drug delivery platform, an alginate-based polymer film, facilitates quick and dependable transmucosal absorption of clinically established and marketed substances. The company also offers reliable and stable supply forms than tablets and other delivery systems such as nasal sprays and orally dissolvable tablets. Klaria Pharma offers its products to customers globally through selected distributors. The company works in partnership with local pharmaceutical companies on clinical trials, registration, marketing and manufacturing. Klaria Pharma is headquartered in Taby, Stockholm, Sweden.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287373[/fusion_builder_row][/fusion_builder_container]